Novo Nordisk is raising its 2026 outlook after a mixed quarter, but slowing stock performance and new competition are forcing the company to reset expectations for its blockbuster Wegovy pill and global expansion strategy
When a company's stock is down nearly 10% year to date and off 38% over three years, as is the case for Novo Nordisk, the pressure on leadership to restore investor confidence is intense. The Danish pharmaceutical giant, known for its diabetes and obesity treatments, is now working to reframe the narrative around its flagship weight-loss drug, the Wegovy pill, after reporting second-quarter 2026 results that both raised guidance and exposed new challenges.
Prescription Growth and Market Competition
Novo Nordisk's Q2 2026 earnings, released August 4, showed that while the company increased its full-year guidance, the most closely watched metric was the pace of new Wegovy prescriptions. The first million prescriptions for the pill took 11 weeks to reach, at a time when there was no direct competition. More recently, the latest million prescriptions were filled in just four weeks, even as a major competitor entered the market and began to fight for share. This acceleration is central to Novo Nordisk's argument that demand for GLP-1 weight-loss drugs remains robust, despite market skepticism about long-term adoption rates.
According to the company, more than five million total prescriptions have been written for the Wegovy pill in the U.S. since launch. For the week ending July 17, weekly prescriptions surpassed 265,000. Notably, about 80% of new patients starting the pill have never used a GLP-1 treatment before, suggesting that the product is expanding the overall market rather than simply shifting existing users from injectable to oral forms. The remaining 20% of new pill users are primarily switching from competitors' products, not from Novo Nordisk's own injectable franchise.
Financial Results and Guidance Update
Novo Nordisk's Q2 2026 financials require careful interpretation due to a significant prior-year comparison. Reported sales rose just 3% at constant exchange rates, held back by a DKK 2.6 billion rebate provision reversal related to the U.S. 340B Drug Pricing Program, which had artificially boosted Q2 2025 results. Adjusted sales, which exclude this distortion, grew 7% at constant exchange rates, driven by GLP-1 volume growth and favorable U.S. rebate adjustments. Adjusted operating profit increased 11%, while reported operating profit fell 16% due to non-cash impairment charges of DKK 6.3 billion, including DKK 4.0 billion tied to the monlunabant program.
The company raised its full-year 2026 guidance for both adjusted sales and adjusted operating profit, citing stronger-than-expected GLP-1 product sales, particularly from the Wegovy pill's U.S. adoption and international expansion. Despite these positive signals, Novo Nordisk's stock (NVO) remains under pressure, down 9.87% year to date as of early August, according to Yahoo Finance.
International Expansion and Pipeline Developments
Beyond the U.S., Novo Nordisk is aggressively rolling out the Wegovy pill in new markets. In June, the company launched the product in the UAE, quickly capturing 50% market share within three weeks despite being the second entrant. The U.K. now has 300,000 active patients, and the European Medicines Agency approved the pill in July based on OASIS 4 trial data showing up to 16.6% mean weight loss. Germany is among the next major European markets targeted for launch.
Meanwhile, the Wegovy 7.2 mg single-dose pen, which demonstrated up to 20.7% mean weight loss in the STEP UP trial, received European approval in July and launched in the U.S. in April, broadening the company's product ladder. However, not all pipeline news was positive: the ZEUS Phase 3 trial for ziltivekimab in cardiovascular disease failed to meet its primary endpoint, contributing to the Q2 impairment charge.
Investor Sentiment and Market Context
Novo Nordisk's leadership is emphasizing the acceleration in prescription growth and the high proportion of new-to-GLP-1 patients as evidence of genuine market expansion. The company's raised guidance is intended to signal operational momentum rather than financial engineering. Yet, with the stock still trading well below its three-year highs, investors remain cautious about whether the current growth trajectory can be sustained, especially as competition intensifies and international launches ramp up.
For context, the company's approach to managing investor expectations echoes recent moves by other major firms facing high-growth scrutiny. For example, Microsoft's Q4 results and Azure's $100 billion milestone prompted a reassessment of tech infrastructure investments, as detailed in this analysis of Microsoft's stock target revision.
Looking ahead, the key questions for Novo Nordisk are whether the rapid prescription growth can continue into the second half of 2026, if European launches will deliver meaningful revenue, and whether the company can maintain its high rate of new-patient capture as the market matures.
In Q2 2026, Novo Nordisk reported adjusted sales growth of 7% at constant exchange rates, with adjusted operating profit up 11%. The company's full-year guidance was raised on the back of strong GLP-1 demand, but reported operating profit declined 16% due to impairment charges. The Wegovy pill's U.S. prescription volume exceeded 265,000 per week by mid-July, and more than five million total prescriptions have been written since launch.
GLP-1 drugs like Wegovy have become a focal point for both pharmaceutical innovation and investor debate. These medications, originally developed for diabetes, have seen rapid adoption for weight management, but their long-term market potential depends on factors such as insurance coverage, regulatory approvals, and patient adherence. As more competitors enter the space and new formulations are introduced, companies must balance aggressive expansion with careful management of expectations and operational risks. For investors, understanding the difference between reported and adjusted results, as well as the impact of one-time charges and market share dynamics, is essential when evaluating the outlook for firms like Novo Nordisk.
